ClinicalTrials.gg

Program

mazdutide

Also written as “IBI362”, “LY3305677” and “Mazdutide”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Overweight · Fatty Liver · Alcoholism, led by 2 companies.

Furthest: phase 3, since Oct 19, 202227 company-led studies, 9 open or runningLicense: Lilly → Innovent, Aug 2019Next primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics208 open or runningphase 3since Oct 19, 2022Jun 5, 2020Dec 31, 2026phase 3 · NCT06884293
Eli Lilly71 open or runningphase 2since Nov 6, 2023Nov 21, 2016Sep 2027phase 2 · NCT06143956

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Nov 21, 2016.

  1. Nov 15, 2022Phase 1 study in OverweightEli Lilly · NCT05623839 · 32 enrolled · United States
  2. Nov 17, 2022Phase 3 study in Diabetes Mellitus, Type 2Innovent Biologics · NCT05628311 · 319 enrolled · China
  3. Mar 20, 20232 phase 1 studiesInnovent Biologics · NCT05815680, NCT05793450
  4. Nov 6, 20232 phase 2 studies in ObesityEli Lilly · NCT06143956, NCT06124807
  5. Dec 1, 20232 phase 3 studiesInnovent Biologics · NCT06164873, NCT06184568
  6. Jul 25, 2024Phase 1 study in Adolescents With ObesityInnovent Biologics · NCT06536023 · 36 enrolled · China
  7. Feb 5, 2025Phase 2 study in AlcoholismEli Lilly · NCT06817356 · 308 enrolled · United States
  8. Feb 19, 2025Phase 2 study in ObesityInnovent Biologics · NCT06862908 · 141 enrolled · China
  9. Mar 11, 2025Phase 3 study in OverweightInnovent Biologics · NCT06884293 · 479 enrolled · China
  10. Apr 7, 2025Phase 2 study in Metabolic Dysfunction-associated Steatohepatitis (MASH)Innovent Biologics · NCT06937749 · 181 enrolled · China
  11. Apr 9, 2025Phase 3 study in Sleep Apnea SyndromesInnovent Biologics · NCT06931028 · 260 planned · China
  12. May 8, 2025Phase 2 study in ObesityInnovent Biologics · NCT07000955 · 98 enrolled · China
  13. Nov 19, 2025Phase 3 study in Adolescents With Obesity or Overweight With Weight-Related ComorbiditiesInnovent Biologics · NCT07255209 · 180 planned · China
  14. Feb 27, 2026Phase 3 study in OverweightInnovent Biologics · NCT07469800 · 336 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in OverweightInnovent Biologics · NCT06884293
  2. May 7, 2027Primary completion: phase 3 study in Sleep Apnea SyndromesInnovent Biologics · NCT06931028
  3. Sep 2027Primary completion: phase 2 study in ObesityEli Lilly · NCT06143956
  4. Oct 31, 2027Primary completion: phase 3 study in Adolescents With Obesity or Overweight With Weight-Related ComorbiditiesInnovent Biologics · NCT07255209

TargetBeta

GLP1R →read by rule
“Mazdutide is a synthetic peptide analog of mammalian oxyntomodulin and a once-weekly dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), under development for the treatment of obesity and type 2 diabetes (T2D).”study text, by rule · the study

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
SafiglipronJiangsu HengRui Medicinephase 319
efpeglenatideruleHanmi Pharmaceuticalphase 313

Studies

All 27 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07469800Overweight · China3RecruitingInnovent BiologicsAug 1, 2026336
NCT07255209Adolescents With Obesity or Overweight With Weight-Related Comorbidities · China3RecruitingInnovent BiologicsOct 31, 2027180
NCT07000955Obesity · China2Active, not recruitingInnovent BiologicsSep 30, 202698
NCT06931028Sleep Apnea Syndromes · China3RecruitingInnovent BiologicsMay 7, 2027260
NCT06937749Metabolic Dysfunction-associated Steatohepatitis (MASH) · China2Active, not recruitingInnovent BiologicsSep 23, 2026181
NCT06884293Overweight · China3Active, not recruitingInnovent BiologicsDec 31, 2026479
NCT06862908Obesity · China2Active, not recruitingInnovent BiologicsSep 24, 2026141
NCT06817356Alcoholism · United States2CompletedEli LillyMar 19, 2026308
NCT06536023Adolescents With Obesity · China1CompletedInnovent BiologicsJul 22, 202536
NCT06184568Diabetes Mellitus, Type 2 · China3CompletedInnovent BiologicsSep 17, 2025349
NCT06164873Obesity · China3Active, not recruitingInnovent BiologicsJun 27, 2025462
NCT06143956Obesity · United States, Argentina2RecruitingEli LillySep 20271,481
NCT06124807Obesity · United States2CompletedEli LillyJan 22, 2025179
NCT05815680Overweight Subjects · China1CompletedInnovent BiologicsAug 18, 202348
NCT05793450Renal Insufficiency · China1CompletedInnovent BiologicsSep 18, 202320
NCT05628311Diabetes Mellitus, Type 2 · China3CompletedInnovent BiologicsOct 25, 2023319
NCT05623839Overweight · United States1CompletedEli LillyJun 27, 202332
NCT05607680Obesity Or Overweight · China3CompletedInnovent BiologicsAug 21, 2023610
NCT05606913Diabetes Mellitus, Type 2 · China3CompletedInnovent BiologicsJan 26, 2024731
NCT04965506Diabetes Mellitus, Type 2 · China2CompletedInnovent BiologicsApr 28, 2022252
NCT04904913Overweight/ Obesity · China2CompletedInnovent BiologicsMar 29, 2023328
NCT04773977Overweight · China1CompletedInnovent BiologicsMar 9, 202124
NCT04466904Diabetes Mellitus, Type 2 · China2CompletedInnovent BiologicsMay 28, 202142
NCT04440345Overweight · China2CompletedInnovent BiologicsJun 16, 202160
NCT03928379Diabetes Mellitus, Type 2 · Germany1CompletedEli LillyJul 8, 202124
NCT03325387Healthy · United Kingdom1CompletedEli LillyAug 3, 201856
NCT02972645Healthy · United Kingdom1CompletedEli LillyJul 14, 201766

How it is read

Names in the registry

  • “IBI362”, 19 entries
  • “LY3305677”, 5 entries
  • “Mazdutide”, 2 entries
  • “IBI362 liquid formulation”, 1 entry
  • “IBI362 lyophilized powder”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.